

Performance in Initiating - Q1: 2017/2018 (1st July 2016 - 30th June 2017) - HRA studies

| Research Ethics Committee Reference Number | IRAS number | Name of Trial | Site Invited | Site Selected | HRA Approval | Site Confirmed by Sponsor | Site Confirmed | Non Confirmation Status | Site Ready to Start | First Patient Recruited | Reasons for delay |
|--|-------------|---|--------------|---------------|--------------|---------------------------|----------------|-------------------------|---------------------|-------------------------|---|
| 16/SS/0014 | 187949 | GEM3: A double blind placebo controlled trial of a combination of methotrexate and gefitinib versus methotrexate alone as a treatment for ectopic pregnancy | 08/11/2016 | 13/01/2017 | 14/10/2016 | 09/02/2017 | 27/02/2017 | NA | 28/04/2017 | 08/06/2017 | Sponsor. Pharmacy had ongoing issues and queries with pharmacy manual |
| 16/SC/0502 | 199315 | ACL Snap: ACL Surgery Necessity in Non Acute Patients. Comparison of the clinical and cost effectiveness of two management strategies for non-acute Anterior Cruciate Ligament (ACL) injury: Rehabilitation versus surgical Reconstruction. (FP and WP) | 31/10/2016 | 06/12/2016 | 16/11/2016 | 02/03/2017 | 14/03/2017 | NA | 12/04/2017 | 18/04/2017 | NHS Provider. PI unexpectedly off sick at FP. WP delays in PI responses. |
| 16/SW/0232 | 201854 | R-RID: multi-centre, double-blind, randomised, controlled clinical trial of Rifaximin to reduce infection in patients admitted to hospital with decompensated cirrhosis | 20/05/2016 | 06/12/2016 | 31/10/2016 | 17/02/2017 | 23/02/2017 | NA | 07/06/2017 | | Sponsor Delays. Amendments required to the protocol before FPH could start recruiting. |
| 16/SC/0651 | 213404 | An evaluation of the tolerance, compliance and acceptability of a ready to use, liquid, high energy, high protein, peptide-based feed for adults in need of nutrition support – a pilot study | 07/12/2016 | 18/01/2017 | 13/01/2017 | 22/05/2017 | 24/05/2017 | NA | | | Sponsor. Feed not yet been manufactured |
| 17/SC/0022 | 215467 | Panorama: A Phase 3, Double-Masked, Randomised Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients with Moderately Severe to Severe Nonproliferative Diabetic Retinopathy | 07/02/2017 | 07/02/2017 | 28/03/2017 | 10/02/2017 | 23/02/2017 | NA | 06/04/2017 | 20/06/2017 | Sponsor. Sponsor delay in negotiation of monitoring visits. Sponsor delay in signing contract |